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more intensive control program should be developed and applied
to children.
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Background: The World Health Organization currently recom-
ends theuseofﬁveArtemisininCombinationTherapies (ACTs) for
he treatment of uncomplicated malaria. To promote compliance
ndease of use in theﬁeld, a ﬁxed-dosed combination (FDC) of arte-
unate and meﬂoquine, ASMQ, was developed through a number
f innovative/creative partnerships.
Methods: The ﬁrst of these partnerships, the multi-partner
ixed-Dose Artesunate-Based Combination Therapies (FACT) Con-
ortium, created by the Drugs for Neglected Diseases initiative
DNDi) and the Special Program for Research and Training in Trop-
cal Diseases (TDR) in 2002, led to the development of ASMQ
DC. Within FACT, the Brazilian government-owned pharmaceu-
ical company, Farmanguinhos/Fiocruz, was the ﬁrst manufacturer
f ASMQ FDC. Additional partnerships were required to progress
owards making it an affordable, widely accessible product.
Results: Different studies in Brazil, India, Thailand and Myan-
ar, spanning from Phase II clinical trials to a large intervention
tudy involving 24,000 patients, have demonstrated efﬁcacy, safety
nd thus therapeutic usefulness of ASMQ FDC. Recently, a small
tudy in Cambodia yielded results in line with National Malaria
rogramme recommendations. The Malaria in Pregnancy Consor-
ium is overseeing the PREGACT trial, to investigate the safety and
fﬁcacy of ACTs, including ASMQ, in pregnant women in Africa.
A technology transfer agreement between Farmanguin-
os/Fiocruz and Cipla, India, will help make the product available
n India and Southeast Asia at affordable prices. In addition,
edicines for Malaria Venture (MMV) and DNDi are working
ogether to decrease the price of meﬂoquine.
A pre-qualiﬁcation dossier was submitted to the WHO in March
010.Assessmentby regulators fromselectedAfricancountrieswill
e facilitated by way of a coordinated review supported by pre-
ualiﬁcation. DNDi is leading the coordinated reviewof ASMQwith
SEAN (Association of Southeast Asian Nations) regulatory author-
ties to obtain drug registration, which in turn can lead to adoption
y malaria programmes.
Conclusion: With today’s emphasis on developing affordable
reatments for use by different patient populations across conti-
ents, successful partnerships are essential. Indeed, making ASMQ
DC available to those who need it has required contributions of
nd collaboration with a number of partners in addition to those
nvolved in the ﬁrst phases of its development.
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Background: One of the common intestinal helminthic infec-
tions is enterobiasis which is caused by the Enterobius vermicularis.
It is estimated to infect over 1,000 million people worldwide and it
is a group infection which predominates in children. Even though
the prevalence of E. vermicularis among children can be extremely
high throughout the world, research on the infection has been
limitedbecause thedisease isnotusually considered tobeofpublic-
health importance. In Korea, there is only scanty information on the
prevalence of E. vermicularis infection. The aim of the present study
was to evaluate the prevalence and risk factors of E. vermicularis
infection among children in Korean provinces and urban areas.
Methods: Children aged 3-6 yearswhowere residents of Busan,
Ulsan, and Yangsan in South Korea were invited to enroll in the
study after their parents had given their consent from July 15th to
29th 2011. A total of 4107 children were examined for E. vermicu-
laris infection using the cellotape anal swab technique. The parents
of tested children were asked to complete questionnaires so as to
ascertain the potential risk factors such as child’s personal hygiene,
sanitary environment and family’s socioeconomic status. The col-
lected data were coded and analyzed using SPSS version 18.0 for
Windows.
Results: The overall rate of being positive for E. vermicularis egg
was 3.9% ranged from 0.0 to 12.5%. The infection rate was related
to gender, thumb sucking, pre-medication of anthelmintics, and
number of siblings. The risk factors signiﬁcantly associated with E.
vermicularis infection were gender (OR 0.607), thumb sucking (OR
0.468) and pre-medication of anthelmintics (OR 4.139).
Conclusion:Wepropose that E. vermicularis infection screening
among children should be continued on a regular basis. In addition,
